Contact
Please use this form to send email to PR contact of this press release:
Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies
TO:
Please use this form to send email to PR contact of this press release:
Trillium Therapeutics Announces Updated Data From Its Ongoing TTI-622 and TTI-621 Dose Escalation Studies
TO: